Pharmafile Logo

Peter Impey

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

Inceptua Medicines Access appoints senior new-hires

The new speciality business unit appoints senior project manager and office manager

Realm Therapeutics appoints Sandy Zweifach as non-executive director

But Matthew Hammond and Daniel Hegglin retire

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

Is AI changing the future of healthcare?

How technology is playing a big role in healthcare

- PMLiVE

What value for innovation in an era dominated by affordability?

Pharma can collaborate but must be clear about its motives

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

- PMLiVE

Novartis’ orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

- PMLiVE

Lucid Group bolster their commitment to agile working with the appointment of a new Head of Operations and Facilities

Thriving businesses often meet unique challenges when transitioning from a start-up to an established medium-sized company. With its numerous successes and exponential expansion over the last ten years, Lucid recognise...

Lucid Group Communications Limited

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

Shining a light on the true cost of patient care

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS

Wilmington Healthcare

- PMLiVE

EMA forges closer ties with HTA umbrella group

Agrees joint work plan with the European Network for Health Technology Assessment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links